Cite
HARVARD Citation
Passamonti, F. et al. (n.d.). S197: NAVITOCLAX PLUS RUXOLITINIB IN JAK INHIBITOR-NAÏVE PATIENTS WITH MYELOFIBROSIS: PRELIMINARY SAFETY AND EFFICACY IN A MULTICENTER, OPEN-LABEL PHASE 2 STUDY. HemaSphere. pp. 98-99. [Online].